MidFirst Bank Purchases Shares of 26,954 Amgen Inc. $AMGN

MidFirst Bank purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 26,954 shares of the medical research company’s stock, valued at approximately $8,822,000.

Several other large investors have also recently added to or reduced their stakes in AMGN. DGS Capital Management LLC raised its stake in Amgen by 17.1% during the 4th quarter. DGS Capital Management LLC now owns 2,089 shares of the medical research company’s stock valued at $684,000 after acquiring an additional 305 shares in the last quarter. Astoria Portfolio Advisors LLC. grew its stake in shares of Amgen by 31.1% in the fourth quarter. Astoria Portfolio Advisors LLC. now owns 1,871 shares of the medical research company’s stock worth $612,000 after purchasing an additional 444 shares in the last quarter. SG Trading Solutions LLC acquired a new position in shares of Amgen during the fourth quarter valued at $1,041,000. Investment Insight Wealth Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at about $205,000. Finally, Monetary Solutions Ltd bought a new stake in shares of Amgen during the fourth quarter valued at about $118,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of recent analyst reports. Barclays assumed coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price for the company. Mizuho upped their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Guggenheim dropped their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Finally, Royal Bank Of Canada upped their target price on Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.42.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by corporate insiders.

Amgen Stock Performance

Shares of AMGN opened at $337.60 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm’s 50 day moving average is $340.96 and its 200-day moving average is $345.81. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The stock has a market capitalization of $182.21 billion, a P/E ratio of 23.49, a P/E/G ratio of 3.43 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.